Journal
MOLECULAR AND CELLULAR ENDOCRINOLOGY
Volume 461, Issue C, Pages 64-78Publisher
ELSEVIER IRELAND LTD
DOI: 10.1016/j.mce.2017.08.014
Keywords
Bazedoxifene; Raloxifene; SERMs; Hypoxia; Neocortical neurons; Neuroprotection; PPAR-gamma; Estrogen receptors
Categories
Funding
- statutory funds of the Institute of Pharmacology PAS, Krakow, Poland
- KNOW - Ministry of Science and Higher Education, Poland
- L'Oreal-UNESCO Poland Fellowship for Women in Science
- Ministry of Science and Higher Education, Poland
Ask authors/readers for more resources
Selective estrogen receptor modulators (SERMs) such as bazedoxifene and raloxifene are recognized to mainly act via estrogen receptors (ERs), but there is no study examining the involvement of PPAR-gamma in their actions, especially in neurons undergoing hypoxia. Little is also known about age-dependent actions of the SERMs on neuronal tissue challenged with hypoxia. In this study, bazedoxifene and raloxifene protected neocortical cells against hypoxia at early and later developmental stages. Both SERMs evoked caspase-3-independent neuroprotection and increased protein levels of ER alpha (66 and 46 kDa isoforms) and PPAR-gamma. In addition, bazedoxifene enhanced expression of ER alpha-regulated Cyp19a1 mRNA. Using double siRNA silencing, for the first time we demonstrated a key role of ERa and PPAR-gamma in the neuroprotective action of the SERMs in neocortical neurons undergoing hypoxia. This study provides prospects for the development of a new therapeutic strategies against hypoxic brain injury that selectively target ERa and/or PPAR-gamma. (C) 2017 Elsevier B.V. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available